ORNBV Orion Oyj Class B

Orion Corporation: Change in Orion Group Executive Management Board as of 30 April 2024

Orion Corporation: Change in Orion Group Executive Management Board as of 30 April 2024

ORION CORPORATION

STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS

7 July 2023 at 14.30 EEST

        

Orion Corporation: Change in Orion Group Executive Management Board as of 30 April 2024

Jari Karlson, the Chief Financial Officer of the Orion Group and member of the Executive Management Board of the Orion Group has announced that he will step down from his position at Orion as of 30 April 2024 and that he will retire. He has worked in his current position since 2002.

Orion has started the recruiting process of the successor of Jari Karlson. Karlson will continue in his current position and as a member of the Executive Management Board of the Orion Group until 30 April 2024.

Orion Corporation

Liisa Hurme



President and CEO
    Olli Huotari



SVP, Corporate Functions
 

                                                

Contact person:

Liisa Hurme, President and CEO

tel. +358 10 426 2874 

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland



Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

 



EN
07/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion and Glykos announce the extension of their research collaboratio...

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs ORION CORPORATION PRESS RELEASE 17 JUNE 2025 at 9.00 EEST         Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs). Under the extended agreement, Orion gain...

 PRESS RELEASE

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan ...

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi ORION OYJ        LEHDISTÖTIEDOTE        17.6.2025 KLO 9.00          Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi Orion Oyj ja Glykos Finland Oy laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien (antibody-drug conjugate, ADC) kehittämiseksi. Laajennettu sopimus antaa Orionille oikeuden hyödyntää Glykosin ADC-teknologioita kolm...

 PRESS RELEASE

U.S. FDA approves third indication of darolutamide for patients with a...

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST           U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy.This third approval is based on positive results from the pivotal Phase III ...

 PRESS RELEASE

Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen dar...

Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen darolutamidille edennyttä eturauhassyöpää sairastavien potilaiden hoidossa ORION OYJLEHDISTÖTIEDOTE3.6.2025 klo 23.30          Yhdysvaltain lääkeviranomainen FDA hyväksyi kolmannen käyttöaiheen darolutamidille edennyttä eturauhassyöpää sairastavien potilaiden hoidossa Darolutamidi on ensimmäinen ja ainoa androgeenireseptorin estäjä, joka on Yhdysvalloissa saanut FDA:lta hyväksynnän levinneen hormonisensitiivisen eturauhassyövän (mHSPC) hoitoon yhdistettynä tavanomaiseen hormonaaliseen hoitoon (androgeenideprivaatioterapi...

 PRESS RELEASE

Orion announces agreement with Shilpa Medicare for Recombinant Human A...

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST         Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited (“Shilpa”), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa’s Recombinant Human Albumin is ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch